Gastrointestinal Stromal Tumors With KIT Exon 11 Deletions Are Associated With Poor Prognosis

This publication has 31 references indexed in Scilit:

• Prognostic Significance of c-kit Mutation in Localized Gastrointestinal Stromal Tumors
  Clinical Cancer Research, 2004
• Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
  Journal of Clinical Oncology, 2003
• KIT Mutations Are Common in Incidental Gastrointestinal Stromal Tumors One Centimeter or Less in Size
  The American Journal of Pathology, 2002
• Inhibition of KIT Tyrosine Kinase Activity: A Novel Molecular Approach to the Treatment of KIT-Positive Malignancies
  Journal of Clinical Oncology, 2002
• The Complexity of KIT Gene Mutations and Chromosome Rearrangements and Their Clinical Correlation in Gastrointestinal Stromal (Pacemaker Cell) Tumors
  The American Journal of Pathology, 2002
• Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study
  The Lancet, 2001
• Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor
  New England Journal of Medicine, 2001
• KIT Extracellular and Kinase Domain Mutations in Gastrointestinal Stromal Tumors
  The American Journal of Pathology, 2000
• Mutations in Exon 11 of c-Kit Occur Preferentially in Malignant versus Benign Gastrointestinal Stromal Tumors and Do Not Occur in Leiomyomas or Leiomyosarcomas
  The American Journal of Pathology, 1999
• Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal Tumors
  Science, 1998